This lack of a direct link to blood-iron levels suggests that the damage to the brain may be caused by other, more complex mechanisms. Professor Olynyk pointed toward the possibility of increased brain injury resulting from systemic inflammation and cellular damage within the body. If the H63D variant predisposes the brain to inflammatory responses or makes neural cells more vulnerable to oxidative stress, these pathways could potentially be treated or managed if scientists can gain a deeper understanding of the underlying processes.
The findings have significant implications for public health and clinical practice, particularly regarding genetic testing. In many Western countries, including Australia, the HFE gene is already routinely tested when doctors suspect a patient may have haemochromatosis—a condition where the body absorbs excessive amounts of iron, leading to organ damage over time. Given the newly discovered link to dementia risk, Professor Olynyk suggested that there may be a case for offering this genetic testing more broadly to men, even in the absence of traditional iron-disorder symptoms.
The ability to identify high-risk individuals through routine testing could be a game-changer for dementia prevention. Professor Paul Lacaze, a co-author from Monash University, emphasized that understanding these genetic nuances is essential for improving outcomes in a country where dementia is a leading cause of disability and death. Currently, more than 400,000 Australians are living with dementia, and men account for approximately one-third of that population. By pinpointing why men with the double H63D variant are more susceptible to the disease, researchers can move toward "precision medicine"—tailoring prevention strategies and treatments to a person’s specific genetic risks.
The strength of these findings is bolstered by the scale and rigor of the ASPREE trial, which provided the foundational data for the study. ASPREE was a massive, double-blind, randomized, placebo-controlled trial involving 19,114 healthy older people across Australia and the United States. While the trial was originally designed to evaluate whether a daily low dose of aspirin could prolong healthy life by preventing heart disease, stroke, or cancer, it inadvertently created what researchers describe as a "treasure trove" of data regarding the aging process.
Because the ASPREE participants were closely monitored over several years, the data set includes detailed information on genetics, lifestyle, and cognitive function. This wealth of information has allowed researchers to investigate a wide array of health issues beyond the original scope of the aspirin study. In this instance, the ASPREE data allowed the research team to track the cognitive health of thousands of individuals and correlate those outcomes with their HFE gene status, providing a level of statistical power that would be difficult to achieve in a smaller study.
